New Drug Approved for Pulmonary Arterial Hypertension

The FDA has approved the endothelin-receptor antagonist Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension.

In clinical trials, the once-daily pill effectively delayed worsening of the condition.

The FDA notes that Letairis may cause birth defects and should not be used during pregnancy.

fda announcement